Determining the MCID for the TOPICS-SF and PROMIS-10 in Older Patients That Suffered an Ischemic Stroke or TIA
Launched by ACADEMISCH MEDISCH CENTRUM - UNIVERSITEIT VAN AMSTERDAM (AMC-UVA) · Jul 3, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to better understand how two specific questionnaires, the TOPICS-Short Form (TOPICS-SF) and the PROMIS Global Health-10 (PROMIS-10), can measure the health and recovery of older patients who have had an ischemic stroke or a Transient Ischemic Attack (TIA). By finding the smallest change in scores that really matters to patients (called the Minimal Clinically Important Difference, or MCID), researchers aim to help doctors understand what these scores mean for patient care.
To participate, you need to be 70 years or older and have experienced an ischemic stroke or TIA within the past week. Unfortunately, if you don't speak Dutch, can't answer questions, or are unable to provide written consent, you won’t be eligible. If you join the trial, you can expect to fill out the questionnaires to help researchers learn more about how these tools can improve care for older patients after a stroke or TIA. Your contribution could make a difference in how healthcare providers understand recovery in similar situations.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • age = 70 years or older at the time of ischemic stroke or TIA;
- • inclusion within a week after diagnosis of ischemic stroke or TIA
- Exclusion Criteria:
- • not speaking Dutch;
- • being unable to answer questions;
- • being unable or not willing to give written informed consent.
About Academisch Medisch Centrum Universiteit Van Amsterdam (Amc Uva)
The Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) is a leading academic medical center in the Netherlands, dedicated to advancing healthcare through innovative research, education, and patient care. Affiliated with the University of Amsterdam, AMC-UvA integrates clinical practice with cutting-edge biomedical research, fostering a multidisciplinary approach to medical challenges. The institution actively engages in clinical trials to enhance treatment options and improve patient outcomes, while promoting collaboration among healthcare professionals, researchers, and academic institutions globally. With a commitment to excellence and a focus on translational medicine, AMC-UvA plays a pivotal role in shaping the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Amsterdam, Noord Holland, Netherlands
Amsterdam, Noord Holland, Netherlands
Patients applied
Trial Officials
Renske van den Berg-Vos, Prof, dr.
Principal Investigator
Amsterdam UMC, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Nathalie van der Velde, Prof, dr
Principal Investigator
Amsterdam UMC, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported